✦ LIBER ✦

Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy

✍ Scribed by Toshiaki Sendo; Naoko Sakai; Yoshinori Itoh; Hiroaki Ikesue; Hiroaki Kobayashi; Toshio Hirakawa; Hitoo Nakano; Ryozo Oishi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Paclitaxel and carboplatin chemotherapy

✍ Luis E Méndez; Antoaneta Mueller; Emery Salom; Víctor Hugo González-Quintero 📂 Article 📅 2003 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 85 KB

Paclitaxel maintenance chemotherapy foll

✍ W.R. ROBINSON; N. DAVIS; A.S. ROGERS 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

Paclitaxel and Platinum Chemotherapy for

✍ Anil K. Sood; Mark S. Shahin; Joel I. Sorosky 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 25 KB

Identification of Risk Factors for Requi

✍ Martee L. Hensley; Dore Lebeau; L.F. Leon; E. Venkatraman; Roger Waltzman; Paul 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Paclitaxel and cisplatin chemotherapy fo

✍ Krystyna Serkies; Ewa Węgrzynowicz; Jacek Jassem 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 221 KB

Venous thromboembolism in ovarian cancer

✍ Saadeh, Feras Abu; Norris, Lucy; O’Toole, Sharon; Gleeson, Noreen 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 477 KB